Chimeric antigen receptor T-cell therapy (CAR-T) is an innovative cancer treatment that modifies a patient's T-cells to recognize and attack cancer cells. The therapy addresses the high unmet clinical need for more effective treatments, particularly for diseases such as lymphoma and leukemia, where current options like chemotherapy and stem cell transplants often fall short. The growing focus on personalized medicine and immune oncology is driving the expansion of CAR-T therapies. In September 2024, the European Society for Blood and Marrow Transplantation (EBMT) reached a milestone of 10,000 CAR-T patients, highlighting its growing significance. Continued focus on improving efficacy and expanding indications is expected to drive further pipeline development and innovation in this field.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to chimeric antigen receptor T-cell therapy (CAR-T).
Chimeric antigen receptor T-cell therapy (CAR-T) is primarily used in the treatment of leukemia and lymphoma, including B-cell acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and diffuse large B-cell lymphoma (DLBCL). These cancers, often resistant to conventional therapies like chemotherapy, have seen remarkable responses to CAR-T, offering hope to patients who previously had limited treatment options.
This product will be delivered within 3-5 business days.
Report Coverage
The Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Drug Pipeline Insight Report by the publisher gives comprehensive insights into chimeric antigen receptor T-cell therapy (CAR-T) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for chimeric antigen receptor T-cell therapy (CAR-T). The chimeric antigen receptor T-cell therapy (CAR-T) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The chimeric antigen receptor T-cell therapy (CAR-T) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with chimeric antigen receptor T-cell therapy (CAR-T) treatment guidelines to ensure optimal care practices.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to chimeric antigen receptor T-cell therapy (CAR-T).
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Drug Pipeline Outlook
Chimeric antigen receptor T-cell therapy (CAR-T) is a groundbreaking immunotherapy that modifies a patient's T-cells to express a receptor specific to cancer cells. The modified T-cells are then reintroduced into the body to target and destroy malignant cells. This treatment is particularly effective in hematological cancers, such as leukemia and lymphoma, and has shown promise in other malignancies.Chimeric antigen receptor T-cell therapy (CAR-T) is primarily used in the treatment of leukemia and lymphoma, including B-cell acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and diffuse large B-cell lymphoma (DLBCL). These cancers, often resistant to conventional therapies like chemotherapy, have seen remarkable responses to CAR-T, offering hope to patients who previously had limited treatment options.
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of chimeric antigen receptor T-cell therapy (CAR-T) drug candidates based on several segmentations, including:By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
- Others
By Route of Administration
- Oral
- Parenteral
- Others
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase I covers a major share of the total chimeric antigen receptor T-cell therapy (CAR-T) clinical trials.Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the chimeric antigen receptor T-cell therapy (CAR-T) pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for chimeric antigen receptor T-cell therapy (CAR-T).Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Clinical Trials Therapeutic Assessment - Competitive Dynamics
The report for the chimeric antigen receptor T-cell therapy (CAR-T) report insights includes the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in chimeric antigen receptor T-cell therapy (CAR-T) clinical trials:- Novartis Pharmaceuticals
- Wugen, Inc.
- Caribou Biosciences, Inc.
- Tcelltech Inc.
- Shanghai Ming Ju Biotechnology Co., Ltd.
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- Suzhou Immunofoco Biotechnology Co., Ltd.
- Arcellx, Inc.
- Bristol-Myers Squibb
- Genentech, Inc.
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for chimeric antigen receptor T-cell therapy (CAR-T). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of chimeric antigen receptor T-cell therapy (CAR-T) drug candidates.Drug: Clarithromycin, Lenalidomide, Dexamethasone and Autologous BCMA-directed CAR T-Cells
The CARTITUDE-5 study, sponsored by Janssen Research & Development, LLC, is evaluating the efficacy of Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by a single dose of Ciltacabtagene Autoleucel (cilta-cel), a CAR-T therapy targeting BCMA, compared to VRd followed by Lenalidomide and Dexamethasone (Rd) in newly diagnosed multiple myeloma patients. The study, enrolling 743 participants, is expected to be completed by December 2034.Genetic: GLPG CAR T-cell therapy
The long-term follow-up study of participants treated with Galapagos Chimeric Antigen Receptor (CAR) T-cell therapies (known as Hesperia) is being sponsored by Galapagos NV. The objective of this Phase 3 study is to evaluate the long-term safety and efficacy of GLPG CAR T-cell therapies for up to 15 years post-infusion. The study, expected to be complete by July 2039, involves 546 participants.Reasons To Buy This Report
The Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for chimeric antigen receptor T-cell therapy (CAR-T). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within chimeric antigen receptor T-cell therapy (CAR-T) pipeline insights.Key Questions Answered in the Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Pipeline Insight Report
- Which companies/institutions are leading the chimeric antigen receptor T-cell therapy (CAR-T) drug development?
- What is the efficacy and safety profile of chimeric antigen receptor T-cell therapy (CAR-T) pipeline drugs?
- Which company is leading the chimeric antigen receptor T-cell therapy (CAR-T) pipeline development activities?
- What is the current chimeric antigen receptor T-cell therapy (CAR-T) commercial assessment?
- What are the opportunities and challenges present in the chimeric antigen receptor T-cell therapy (CAR-T) drug pipeline landscape?
- What is the efficacy and safety profile of chimeric antigen receptor T-cell therapy (CAR-T) pipeline drugs?
- Which company is conducting major trials for chimeric antigen receptor T-cell therapy (CAR-T) drugs?
- Which companies/institutions are involved in chimeric antigen receptor T-cell therapy (CAR-T) collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in chimeric antigen receptor T-cell therapy (CAR-T)?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Chimeric Antigen Receptor T-Cell Therapy (CAR-T)
4 Patient Profile: Chimeric Antigen Receptor T-Cell Therapy (CAR-T)
5 Chimeric Antigen Receptor T-Cell Therapy (CAR-T): Epidemiology Snapshot
6 Chimeric Antigen Receptor T-Cell Therapy (CAR-T): Market Dynamics
7 Chimeric Antigen Receptor T-Cell Therapy (CAR-T): Key Facts Covered
8 Chimeric Antigen Receptor T-Cell Therapy (CAR-T), Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Chimeric Antigen Receptor T-Cell Therapy (CAR-T), Key Drug Pipeline Companies
